Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Summary of Consolidated Subsidiaries (Details)

v3.23.1
Summary of Significant Accounting Policies - Summary of Consolidated Subsidiaries (Details)
12 Months Ended
Mar. 31, 2023
Virax Biolabs Group Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction Cayman Island
Incorporation Date Sep. 02, 2021
Virax Biolabs (UK) Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction United Kingdom
Incorporation Date Aug. 19, 2021
Ownership 100.00%
Virax Biolabs Limited (FKA- Shanghai Biotechnology Devices Ltd)  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction Hong Kong
Incorporation Date Apr. 14, 2020
Ownership 100.00%
ViraxImmune T-Cell Medical Device Company Limited (FKA- Stork Nutrition Asia Limited)  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction Hong Kong
Incorporation Date Jan. 16, 2017
Ownership 100.00%
Virax Biolabs Pte. Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction Singapore
Incorporation Date May 04, 2013
Ownership 95.65%
Logico Bioproducts Corp.  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction BVI
Incorporation Date Jan. 21, 2011
Ownership 95.65%
Shanghai Xitu Consulting Co., Ltd (FKA- Shanghai Logico Bioproducts)  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction PRC
Incorporation Date Oct. 27, 2017
Ownership 95.65%
Virax Biolabs USA Management, Inc.  
Disclosure of reclassifications or changes in presentation [line items]  
Jurisdiction USA
Incorporation Date Jan. 08, 2022
Ownership 100.00%